SANA Sana Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—
Leverage & solvency
Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $131.98M | $215.67M | $261.81M | $285.88M | $248.63M |
| SG&A expense | $44.30M | $64.04M | $73.30M | $71.56M | $50.41M |
| Operating income | -$250.32M | -$272.72M | -$293.14M | -$272.56M | -$356.91M |
| Pretax income | — | — | — | — | -$355.93M |
| Income tax | $0 | — | — | — | — |
| Net income | -$244.17M | -$266.76M | -$283.25M | -$269.48M | -$355.93M |
| EBITDA | -$237.52M | -$257.22M | -$275.64M | -$256.96M | -$345.81M |
| EPS (basic) | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 |
| EPS (diluted) | -0.96 | -1.16 | -1.46 | -1.43 | -2.14 |
| Weighted avg. shares (diluted) | 253.23M | 230.89M | 194.54M | 188.34M | 166.43M |
| Balance sheet | |||||
| Cash & equivalents | $71.87M | $131.40M | $133.52M | $187.27M | $261.85M |
| Short-term investments | $66.51M | $24.93M | $71.68M | $247.20M | $297.97M |
| Current assets | $148.68M | $160.81M | $213.51M | $444.44M | $558.10M |
| PP&E, net | $26.91M | $77.31M | $70.69M | $66.92M | $65.46M |
| Goodwill | $140.63M | $140.63M | $140.63M | $140.63M | $140.63M |
| Intangibles | $59.20M | $59.20M | $59.20M | $59.20M | $59.20M |
| Total assets | $416.89M | $501.02M | $565.30M | $822.72M | $1.13B |
| Current liabilities | $78.73M | $45.43M | $64.49M | $111.50M | $99.23M |
| Total liabilities | $256.01M | $250.52M | $277.79M | $323.40M | $400.90M |
| Shareholders' equity | $160.88M | $250.50M | $287.51M | $499.31M | $728.50M |
| Shares outstanding | 266.73M | 223.92M | 197.86M | 191.02M | 184.93M |
| Cash flow statement | |||||
| Operating cash flow | -$143.83M | -$223.15M | -$253.58M | -$290.05M | -$251.05M |
| Capital expenditure | $938,000 | $33.43M | $20.03M | $20.88M | $29.86M |
| Free cash flow | -$144.77M | -$256.58M | -$273.61M | -$310.93M | -$280.92M |
| Investing cash flow | -$40.24M | $17.45M | $172.01M | $210.56M | -$245.80M |
| Financing cash flow | $128.73M | $199.75M | $31.65M | $4.91M | $631.75M |
| Depreciation & amortization | $12.80M | $15.50M | $17.50M | $15.60M | $11.10M |
| Stock-based compensation | $25.46M | $37.68M | $35.53M | $38.34M | $22.36M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.